MANE heads into this week's key catalyst event with short sellers piling back in at the fastest pace in months — even as the stock has nearly doubled since April.
The short interest story here is one of conviction against momentum. SI as a percentage of free float has climbed from roughly 6% in late April to nearly 10% — the highest level in the 30-day window — before a one-day drop on May 26 pulled it back to 9.7%. That single-day 7% reduction in shares short may reflect short-term covering ahead of Saturday's binary event: Veradermics is set to present topline results from its Phase 2/3 '302' study of VDPHL01 at the 2026 World Congress for Hair Research on May 30. With a market cap of $4.3 billion and next earnings on June 26, the readout is the clearest near-term inflection point on the calendar. The shorts that rebuilt through the second half of May — from 1.5 million shares short on May 4 to a peak of 2.85 million by May 19-22 — are holding meaningful positions into that event.
The lending market tells a nuanced story about how hard it is to press the short. Cost to borrow has collapsed from a 30-day peak of roughly 7.4% in mid-April to just 2.36% now — a drop of over 56% across the month — indicating that supply of borrowable shares expanded sharply relative to demand even as shorts were rebuilding positions. Availability confirms this: at 162% of short interest, there is comfortably more borrow available than shares already lent, well above the 52-week trough of 72% touched on April 30. The borrow market is not signalling a squeeze. The ORTEX short score, however, remains elevated at 65.4 and was as high as 69.9 as recently as May 19 — suggesting the composite view of short positioning remains notably high even after the week's partial retreat.
The Street is broadly constructive, though the gap between analyst targets and recent price action deserves scrutiny. Citigroup raised its price target from $120 to $135 on May 18, maintaining a Buy rating — the most recent action from a named firm, and the most relevant datapoint given its timing relative to the conference presentation. Leerink Partners raised its target from $75 to $90 in late April, also holding Outperform. The consensus mean target is $131, which compares to the current price of $102.50 — implying roughly 28% upside in analyst models. Note that both Citi's current $135 and the mean $131 are above the stock's current level, so the Street's optimism is intact even after a 51% one-month rally. The company carries negative PE and EV/EBITDA multiples, as expected for a clinical-stage pharmaceutical — valuation is entirely thesis-driven at this point.
Institutional ownership flags how quickly the register formed. SR One Capital Management nearly tripled its position last quarter, adding over 2.2 million shares. FMR, Viking Global, Artal, Adage, JP Morgan Asset Management, and Aberdeen all appear to have initiated positions in Q1 2026, collectively representing hundreds of millions in new inflows. Citadel added 1.26 million shares in Q1. The insider data is now stale — the last recorded trades were a February cluster of buying between $17 and $38, mostly by Suvretta Capital Management and a venture capital 10% owner. At the time of those trades, the stock traded at a fraction of today's $102.50. Those buyers are deeply in profit.
The two prior earnings prints both produced negative one-day reactions: -3.6% on March 30 and -0.9% on May 12, with a -7.5% five-day drift following the March event. Neither moves were catastrophic, but both confirm that good news has previously been a "sell the print" dynamic on this name. The May 30 conference presentation is not an earnings event, but it is the closest thing to a binary catalyst before the June 26 earnings date. With SI near 10% of float, a rapidly formed institutional register, analyst targets above current levels, and borrow conditions loose enough to short without friction, the setup heading into the weekend readout is precisely where the bulls' confidence and the bears' conviction collide.
See the live data behind this article on ORTEX.
Open MANE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
